Navigation Links
Is it Possible to Change Prescribing Habits?

In the US more than 770,000 people are injured or die each year in hospitals from adverse drug events (ADEs), which can cost a hospital, depending on its size, about US$5.6 million every year, excluding ADE-associated costs for malpractice and litigation and the personal costs of injuries to patients.

Nationally, hospital expenses to treat patients who have ADEs during hospital admission are enormous: between $1.6 billion and $5.6 billion annually. The cost to patients is also high and not just monetary: those who have an ADE spend on average 8?2 days longer in the hospital than patients who do not have an ADE, and their admission costs $16,000 to $24,000 more.

One way for hospitals to tackle the problem of medication errors is to install computerized monitoring systems, which can reduce ADEs by 28%?5%. Apart from the obvious benefits to patients, these systems can save hospitals as much as $500,000 annually in direct costs. However, despite the potential, fewer than 10% of hospitals have implemented such systems.

Less is known about the value of such systems in an outpatient setting. Now, Andrew Steele and colleagues from Denver have tested a computerized physician order entry (CPOE) system in a US hospital's outpatient clinic. The main purpose of the study was to determine the impact of using computerized alerts to improve the prescribing of medications in the outpatient setting. Studies have shown that 18%?5% of patients might have an ADE in the outpatient environment. This study evaluated a CPOE system alongside an integrated computer-based clinical-decision support system.

It focused on a very specific type of clinical-decision support system: the use of a rules technology to prevent drug–laboratory ADEs. The way the system worked was that providers ordered medications on a computer and an alert was displayed if a relevant drug–laboratory interaction existed.

Comparisons were made between baseline and post-intervention per iods. Provider ordering behavior was monitored, focusing on the number of medication orders not completed and the number of rule-associated laboratory test orders initiated after alert display. The investigators found that the rule processed 16,291 times during the study period on all possible medication orders: 7,017 during the pre-intervention period (prescribing doctors did not receive alerts) and 9,274 during the post-intervention period (prescribing doctors received alerts). During the post-intervention period, an alert was displayed for 11.8% (1,093 out of 9,274) of the times the rule processed, with 5.6% of alerts being for “missing laboratory values,?6.0% for “abnormal rule-associated laboratory?values, and 0.2% for both types of problems.

Providers did pay attention to the alerts; they increased ordering of the rule-associated laboratory test when an alert was displayed (39% at baseline versus 51% post-intervention, p < 0.001), thus showing that the rules had a significant ability to change the ordering behavior of the provider, said the authors. The strongest effect occurred when providers where alerted to “missing?laboratory results (42% increase), the investigators noted. There was less of an effect on ordering behavior when the alert informed the provider of the existence of an abnormal laboratory value (23% increase), which may imply that the cutoff values for the “abnormal?trigger were set too low, suggested the authors. However, there was only a modest effect on halting the ordering of medications, and this was limited to occasions in which the alert presented an abnormal laboratory value in which case there was almost a doubling in order cessation.

There are limitations to the study. For example, the intervention focused on a specific group of drug–laboratory interactions and thus the results may not be generalizable to other types of interventions. In addition, the setting was a single primary-care clinic outpatient setting within a large public-health-integrated health-care delivery system, and results may be different in other settings such as hospitals and private physician offices. However, changing prescriber practice at all is not easy to achieve and this approach thus warrants further research.


'"/>

Source:PLoS Medecine


Related biology news :

1. Stem Cells Found In Cerebellum; Possible Cell of Origin for Childhood Brain Tumors
2. Possible treatment found for chemobrain
3. Possible brain hormone may unlock mystery of hibernation
4. Possible birthplace of malignant brain tumors identified
5. Iron Deficiency Sparks Dramatic Changes In Gene Expression
6. Scientists Propose Sweeping Changes to Naming of Bird Neurosystems to Acknowledge Their True Brainpower
7. FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
8. Some Brain Cells Change Channels To Fine-tune The Message
9. Some Brain Cells Change Channels
10. Change in gene may be underlying molecular defect in some colorectal cancers
11. Methamphetamine Abuse, HIV Infection Cause Changes in Brain Structure
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
(Date:2/6/2017)... According to Acuity Market Intelligence, ongoing ... to continue to embrace biometric and digital identification ... Border Control (ABC) eGates and 1436 Automated Passport ... 163 ports of entry across the globe. Deployments ... combined CAGR of 37%. APC Kiosks reached 75% ...
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... February 27, 2017 Four US ... evaluation today, and they are: Anthera Pharmaceuticals Inc. (NASDAQ: ... California Inc. (NASDAQ: PACB), and Conatus Pharmaceuticals Inc. (NASDAQ: ... ETF Trends, market observers are growing more bullish on ... enact reforms to free cash held overseas for tax ...
(Date:2/26/2017)... ... ... Rob Lowe is a well recognized television personality, so it seems natural he would ... important to the American public and important to society at large. An upcoming episode ... the world for a few years. , The climate and how we relate to ...
(Date:2/24/2017)... KNOXVILLE, Tenn. , Feb. 24, 2017 /PRNewswire/ ... ) ("Provectus" or the "Company"), a clinical-stage oncology ... information regarding the deadline to participate in its ... million units, consisting of shares of common stock ... stockholders and holders of listed warrants. ...
(Date:2/24/2017)... Staten Island, NY (PRWEB) , ... February 24, 2017 , ... ... exponential rate. Founded in late 2014, FireflySci had the goal of bringing their ... 2017, that goal continues to shape the path that FireflySci is going on as ...
Breaking Biology Technology: